AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF DCLL9718S IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) OR DCLL9718S IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED AML UNSUITABLE FOR INTENSIVE INDUCTION CHEMOTHERAPY
Study of Experimental Drug in Patients with Acute Myeloid Leukemia (AML)
Sponsor: Genentech, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR5267
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the safety of DCLL9718S at different dose levels, alone or in combination with azacitidine. DCLL9718S is an experimental drug manufactured by Genentech that is designed to inhibit tumor growth. The drug is being tested in clinical trials and has not been approved by the U.S. Food and Drug Administration (FDA) and/or any other regulatory authorities for any indication.
This study is closed
Investigator
Joseph Jurcic, MD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with acute myeloid leukemia (AML)? Yes No
Do you have a life expectancy of 12 weeks or more? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE